May 12, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

CRADA with NIAID on BCV for Post-Transplant Lymphoproliferative Disorder (PTLD) Extended for Three Years – SymBio to Advance Development of Brincidofovir (BCV) for EBV-Associated Diseases —

TOKYO, Japan, May 12, 2026 -- SymBio Pharmaceuticals Limited ("SymBio" or the "Company") today announced that it has agreed to extend its Cooperative Research and Development Agreement ("CRADA") for three years with the research team led by Dr. Jeffrey Cohen at the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the U.S. National Institutes of Health ("NIH"), for post-transplant lymphoproliferative disorder ("PTLD").

Through collaborative research with the NIAID research team, SymBio has successfully established an animal model of EBV-reactivation using humanized mice. Going forward, the Company plans to utilize this animal model to evaluate the therapeutic effect of BCV and obtain insights to support the initiation of clinical trials.

Statement from Fuminori Yoshida, President and CEO: "Treatment options remain limited for post-transplant lymphoproliferative disorder (PTLD) and EBV-associated lymphoproliferative disease ("LPD"). Together with the NIAID research team, SymBio will further advance this research toward the development of new treatment approaches."

The Company does not expect this matter to have a material impact on its consolidated financial results for the fiscal year ending December 2026.

[Contact]
Investor Relations
Tel: +81 (0)3 5427 1125

Note

1. Cooperative Research and Development Agreement (CRADA) with NIAID

In April 2023, SymBio entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The purpose of this agreement is to evaluate the antiviral activity of BCV against EBV and to conduct preclinical studies targeting EBV-associated lymphoproliferative disease. With this renewal, the term of the CRADA will be extended to April 2029. BCV has demonstrated potent antiviral activity against EBV, and SymBio intends to further evaluate its therapeutic potential through suppression of reactivated EBV replication and to build robust supporting evidence.

2. About Post-Transplant Lymphoproliferative Disorder (PTLD)

Epstein-Barr virus (EBV) is a virus that remains latent in more than 90% of adults, with its proliferation normally kept under control by the immune system. However, when immune function is weakened, such as through the use of immunosuppressive agents following organ transplantation, EBV may reactivate, causing abnormal proliferation of lymphocytes, particularly B cells, and leading to PTLD. PTLD is a refractory disease that can progress extremely rapidly, and survival rates are very low once the disease becomes severe. Existing approaches, including conventional chemotherapy and reduction of immunosuppressive therapy, are often insufficient, creating a strong need for new treatment strategies that directly target viral replication itself.

BCV's Business Strategy Based on Three Therapeutic Pillars

Since acquiring the global license to BCV in September 2019, SymBio has been conducting collaborative research with world-class research institutions to unlock BCV's potential in three therapeutic areas. Currently, our management resources and development efforts are centered on three therapeutic pillars: (1) viral infections post-HSCT, (2) hematologic malignancies and solid tumors, and (3) neurodegenerative diseases. SymBio is focusing on its business globally to maximize the business value of BCV.